Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that serves as a source of calories and energy, replenishing blood glucose levels. Sodium chloride provides electrolytes for fluid and electrolyte balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
FDA: For intravenous administration as a source of water, calories, and electrolytes in patients requiring parenteral fluid therapy.,Off-label: Treatment of hypovolemia, hyponatremia, and hyperkalemia.
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; dosing depends on patient's fluid and electrolyte needs. Typical adult dose: 0.9% sodium chloride equivalent at 100-200 m L/hour, but adjust based on serum sodium, glucose, and volume status.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose: Not applicable as it is rapidly metabolized. Sodium: Not applicable (homeostatically regulated). Chloride: Not applicable (follows sodium). Clinical context: Half-life concepts do not apply; steady state for electrolytes depends on infusion rate and renal function.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the tricarboxylic acid cycle. Sodium chloride is not metabolized.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of unchanged dextrose. Sodium and chloride are primarily excreted renally with >90% of filtered load reabsorbed; excess is excreted in urine. Biliary/fecal: Negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: Not bound. Sodium: Not bound. Chloride: Not bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: 0.2–0.3 L/kg (total body water). Sodium and chloride: 0.2–0.3 L/kg (extracellular fluid). Clinical meaning: Distributes predominantly in extracellular fluid; expands plasma and interstitial volume.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100% (by definition).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For GFR 30-60 m L/min: no specific adjustment; monitor volume status and serum electrolytes. For GFR <30 m L/min: use with caution; may require volume restriction and monitoring for hyperchloremic metabolic acidosis.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific Child-Pugh based adjustments; use with caution in patients with cirrhosis due to risk of fluid overload and hyponatremia.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based infusion: 0.9% sodium chloride equivalent at 4-8 m L/kg/hour; adjust based on serum sodium and glucose levels. For maintenance: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, 20 m L/kg/day for additional weight.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution; lower initial infusion rates (e.g., 50-100 m L/hour) due to increased risk of fluid overload and electrolyte disturbances. Monitor serum sodium and glucose frequently.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None.
None.
Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes mellitus or impaired glucose tolerance.,Risk of fluid overload, especially in patients with renal impairment or cardiac disease.,Risk of dilutional hyponatremia, particularly in patients with increased ADH production.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to any component.,Clinically significant hyperglycemia or hypernatremia.,Use in patients with intracranial or intraspinal hemorrhage, or conditions causing severe dehydration with anuria.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No direct food interactions. However, sodium content (0.225% = 34.5 m Eq/L) should be considered in patients on sodium-restricted diets. Dextrose may affect glucose tolerance; monitor intake in diabetic patients.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose and sodium chloride are physiologic components that are not known to be teratogenic; no increased risk of congenital anomalies has been reported.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Excreted in breast milk; M/P ratio not established. Dextrose and sodium chloride are normal constituents of milk; use during lactation is considered safe.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dose adjustment required; pharmacokinetics of dextrose and sodium chloride are not significantly altered in pregnancy. Use caution in patients with gestational diabetes or preeclampsia.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This hypotonic solution (225 m Osm/L) is suitable for maintenance hydration in normonatremic patients. Monitor serum sodium to avoid hyponatremia, especially in children, elderly, or those with impaired renal function. Do not use for resuscitation or in patients with hyponatremia. Contains 5% dextrose providing 170 kcal/L; consider in catabolic states.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This solution provides water, sugar, and salt to maintain hydration and energy.,Tell your doctor if you have swelling (edema), heart failure, or kidney problems.,Inform your doctor if you are on a low-sodium diet.,You may experience weight gain or swelling if too much fluid is given.,Do not self-adjust the infusion rate.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that serves as a source of calories and energy, replenishing blood glucose levels. Sodium chloride provides electrolytes for fluid and electrolyte balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is: Intravenous infusion; dosing depends on patient's fluid and electrolyte needs. Typical adult dose: 0.9% sodium chloride equivalent at 100-200 m L/hour, but adjust based on serum sodium, glucose, and volume status.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic components that are not known to be teratogenic; no increased risk of congenital anomalies has been reported.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.